Drug Profile
GRF 6019
Alternative Names: AKST 6019; ALK 6019; GRF6019; Plasma-based therapeutic; Plasma-based therapeutic - Alkahest/GrifolsLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Alkahest; Grifols
- Developer Alkahest
- Class Anti-inflammatories; Antidementias; Antiparkinsonians; Neuroprotectants; Nootropics
- Mechanism of Action Neurogenesis stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Alzheimer's disease
Most Recent Events
- 09 Mar 2021 Phase-II development is ongoing for Alzheimer's disease in USA (Alkahest pipeline, March 2021)
- 09 Dec 2019 Efficacy and safety data from a phase I trial in Alzheimer’s Disease presented at the 12th Annual Clinical Trials on Alzheimer’s Disease (CTAD-2019)
- 05 Aug 2019 Efficacy adverse events data from a phase II trial in Alzheimer's disease released by Alkahest